Vertex Pharmaceuticals (VRTX) Revenue (2009 - 2026)

Vertex Pharmaceuticals has reported Revenue for 18 years, with the latest figure at $3.3 billion in Q2 2026.

• On a quarterly basis, Revenue rose 12.45% year-over-year to $3.3 billion in Q2 2026; TTM through Jun 2026 was $12.6 billion, a 10.23% increase from a year earlier, with the FY2025 full-year figure at $12.0 billion, up 8.9% from the prior year.
• Revenue was $3.3 billion for Q2 2026 at Vertex Pharmaceuticals, up from $3.0 billion in the prior quarter.
• The five-year high for Revenue was $3.3 billion in Q2 2026, with the low at $2.1 billion in Q1 2022.
• Average Revenue over 5 years is $2.7 billion, with a median of $2.7 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Revenue increased 22.46% in 2022, then grew 2.96% in 2025.
• Over 5 years, Revenue stood at $2.3 billion in 2022, then climbed by 9.34% to $2.5 billion in 2023, then grew by 15.66% to $2.9 billion in 2024, then grew by 9.55% to $3.2 billion in 2025, then increased by 4.51% to $3.3 billion in 2026.
• The last three Revenue figures came in at $3.3 billion (Q2 2026), $3.0 billion (Q1 2026), and $3.2 billion (Q4 2025), per Business Quant data.